Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Autor: Banerjee, Susana N., Ring, Kari Lassen, Van Nieuwenhuysen, Els, Fabbro, Michel, Aghajanian, Carol, Oaknin, Ana, Colombo, Nicoletta, Santin, Alessandro, Clamp, Andrew R., Moore, Kathleen N., Rose, Peter Graham, O'Malley, David M., Chon, Hye Sook, Salinas, Erin A, Prendergast, Emily N, Lustgarten, Stephanie, Rodrigues, Manuel, Gennigens, Christine, Monk, Bradley J., Grisham, Rachel N.
Zdroj: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5515-5515, 1p
Databáze: Supplemental Index